Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Drug Excretion: Overview

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

Renal Drug Clearance: Overview

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...

Renal Drug Excretion: Glomerular Filtration

Renal Drug Excretion: Glomerular Filtration

The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles.

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Composite Surrogate Markers of Insulin Resistance: A Real-World Study Using METS-IR and SPISE.

Journal of clinical medicine·2026

Same author

Assessment of attitudes toward weight loss pharmacotherapy among Greek patients living with obesity: a questionnaire-based study.

Hormones (Athens, Greece)·2026

Same author

Risk Factors Associated with Community-Onset Infections Due to Multidrug-Resistant Organisms.

Antibiotics (Basel, Switzerland)·2025

Same author

Stroke in Transcatheter Aortic Valve Implantation (TAVI): A Comprehensive Review.

Journal of clinical medicine·2025

Same author

Cardiovascular disease burden attributable to estimated glomerular filtration rate: Insights from the ATTICA study (2002-2022).

Annals of epidemiology·2025

Same author

Structural radial artery modifications following transradial access: Mechanisms, clinical implications, and preventive strategies.

World journal of cardiology·2025

Search research articles

Related Experiment Video

Updated: May 13, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

Fenofibrate and the kidney: an overview.

Michael S Kostapanos¹, Matilda Florentin, Moses S Elisaf

¹Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.

European Journal of Clinical Investigation

|March 14, 2013

Summary

Fenofibrate may cause temporary increases in serum creatinine (SCr), but it is not nephrotoxic. Close monitoring of SCr is advised, especially for high-risk patients, with discontinuation if levels rise by 30%.

Related Experiment Videos

Last Updated: May 13, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

Area of Science:

Nephrology
Pharmacology
Cardiovascular Medicine

Background:

Fenofibrate is a long-standing treatment for atherogenic dyslipidemia.
Concerns exist regarding fenofibrate's impact on renal function due to reported serum creatinine (SCr) increases.

Purpose of the Study:

To review existing literature on fenofibrate's effects on kidney function.
To clarify the relationship between fenofibrate use and changes in SCr and estimated glomerular filtration rate (eGFR).

Main Methods:

This study is a narrative review of clinical literature.
The review analyzes studies investigating fenofibrate's impact on renal parameters.

Main Results:

Fenofibrate use is associated with transient, reversible increases in SCr and declines in eGFR.
Risk factors include older age, impaired renal function, high-dose fenofibrate, and concurrent use of ACE inhibitors or ARBs.
Long-term data suggest fenofibrate may slow renal function decline and albuminuria, potentially offering protection in diabetic nephropathy and hypertensive glomerulosclerosis.

Conclusions:

Fenofibrate is unlikely to be nephrotoxic, despite transient SCr elevations.
Monitoring SCr is crucial, particularly in high-risk individuals.
Discontinuation of fenofibrate may be considered if SCr increases by 30% or more.